BR0009296A - Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto - Google Patents

Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto

Info

Publication number
BR0009296A
BR0009296A BR0009296-7A BR0009296A BR0009296A BR 0009296 A BR0009296 A BR 0009296A BR 0009296 A BR0009296 A BR 0009296A BR 0009296 A BR0009296 A BR 0009296A
Authority
BR
Brazil
Prior art keywords
neural
cgs
cells
neural activity
prevent
Prior art date
Application number
BR0009296-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Meir Shinitzky
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of BR0009296A publication Critical patent/BR0009296A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
BR0009296-7A 1999-03-25 2000-03-24 Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto BR0009296A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12917899A IL129178A0 (en) 1999-03-25 1999-03-25 Induction of nerve generation
PCT/IL2000/000185 WO2000057865A2 (en) 1999-03-25 2000-03-24 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation

Publications (1)

Publication Number Publication Date
BR0009296A true BR0009296A (pt) 2001-12-18

Family

ID=11072645

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0009296-7A BR0009296A (pt) 1999-03-25 2000-03-24 Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto

Country Status (16)

Country Link
US (1) US6914056B1 (https=)
EP (1) EP1162959B1 (https=)
JP (1) JP2002540146A (https=)
KR (1) KR20010112364A (https=)
CN (1) CN1348375A (https=)
AT (1) ATE290385T1 (https=)
AU (1) AU768911B2 (https=)
BR (1) BR0009296A (https=)
CA (1) CA2368597A1 (https=)
DE (1) DE60018554T2 (https=)
HK (1) HK1042038A1 (https=)
IL (1) IL129178A0 (https=)
MX (1) MXPA01009650A (https=)
NZ (1) NZ514525A (https=)
RU (1) RU2247557C2 (https=)
WO (1) WO2000057865A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1106180B1 (en) 1999-12-08 2003-11-12 Centre National de la Recherche Scientifique (CNRS) Use of hymenialdisine or derivatives thereof in the manufacture of medicaments
JP4836345B2 (ja) * 2001-04-13 2011-12-14 きみ子 室伏 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤
JP4815063B2 (ja) * 2001-04-13 2011-11-16 きみ子 室伏 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び/又は生存の促進のための薬剤
IL148665A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phate and their action as cell stimulants
IL148668A0 (en) * 2002-03-13 2002-09-12 Yeda Res & Dev Derivatives of 1,3-cyclic propandiol phosphate and their action in differentiation therapy
US20050171084A1 (en) * 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
JP4162927B2 (ja) 2002-06-11 2008-10-08 きみ子 室伏 カルバ環状ホスファチジン酸誘導体
WO2006097924A2 (en) * 2005-03-14 2006-09-21 Yeda Research And Development Company Ltd. Cyclic phosphates as plant growth regulators
JP5695293B2 (ja) * 2006-04-26 2015-04-01 富山化学工業株式会社 アルキルエーテル誘導体またはその塩を含有する神経細胞新生誘導剤および精神障害治療剤
WO2008081580A1 (ja) * 2006-12-28 2008-07-10 Ochanomizu University 環状ホスファチジン酸誘導体を含む鎮痛剤
US8420848B2 (en) 2009-01-09 2013-04-16 Sigma-Aldrich Co. Llc Process for the synthesis of beta glycerol phosphate
WO2011065480A1 (ja) * 2009-11-26 2011-06-03 国立大学法人お茶の水女子大学 神経細胞死抑制剤
WO2014115885A1 (ja) 2013-01-28 2014-07-31 国立大学法人お茶の水女子大学 脱髄疾患治療薬
EP2807925A1 (en) * 2013-05-26 2014-12-03 Symrise AG Antimicrobial compositions
AU2016366977A1 (en) * 2015-12-08 2018-07-12 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL63037A (en) * 1981-06-04 1985-12-31 Israel State Dioxaphosphorinanes,their preparation and pharmaceutical and veterinary compositions containing them
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
JPH06228169A (ja) * 1993-02-05 1994-08-16 Sagami Chem Res Center 1−o−アシルグリセロール2,3−ホスフェートの製造法
JPH07149772A (ja) * 1993-11-26 1995-06-13 Sagami Chem Res Center タンパク質リン酸化酵素cの活性促進剤
JPH07258278A (ja) * 1994-03-18 1995-10-09 Sagami Chem Res Center 1−O−アシルグリセロール−2,3−ホスフェート誘導体を有効成分とするDNAポリメラーゼαの阻害剤
JPH0925235A (ja) * 1995-07-13 1997-01-28 Sagami Chem Res Center 1−o−アシルグリセロール−2,3−ホスフェート誘導体を有効成分とするがん転移抑制剤
US6150345A (en) * 1998-08-10 2000-11-21 Regents Of The University Of California Methods for promoting survival of myelin producing cells
IL129179A0 (en) * 1999-03-25 2000-02-17 Yeda Res & Dev Cyclic glycerophosphates and analogs thereof

Also Published As

Publication number Publication date
AU3451700A (en) 2000-10-16
CA2368597A1 (en) 2000-10-05
IL129178A0 (en) 2000-02-17
EP1162959A2 (en) 2001-12-19
NZ514525A (en) 2003-10-31
RU2247557C2 (ru) 2005-03-10
EP1162959B1 (en) 2005-03-09
AU768911B2 (en) 2004-01-08
WO2000057865A3 (en) 2001-06-28
HK1042038A1 (zh) 2002-08-02
US6914056B1 (en) 2005-07-05
MXPA01009650A (es) 2002-07-02
JP2002540146A (ja) 2002-11-26
WO2000057865A9 (en) 2001-11-15
KR20010112364A (ko) 2001-12-20
DE60018554D1 (de) 2005-04-14
CN1348375A (zh) 2002-05-08
ATE290385T1 (de) 2005-03-15
DE60018554T2 (de) 2006-04-13
WO2000057865A2 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
BR0009296A (pt) Composição farmacêutica, processos para induzirpromoção de diferenciação de células neurais decélulas-alvo, para promover atividade neural emum indivìduo, e para prevenção ou tratamento dedistúrbios e doenças que podem ser prevenidos outratados por meio de promoção de diferenciaçãode células neurais e/ou de atividade neural, e, usode um composto
Karczmar Acute and long lasting central actions of organophosphorus agents
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
DE236684T1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
ATE444077T1 (de) Präventiva und therapeutika für mit demyelinisierung-assozierten erkrankungen
EP0616032A3 (en) Preventive or therapeutic agents against Alzheimer's disease, a screening method and the human tau kinase protein.
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
BR9714677A (pt) "enantiÈmeros 3-piridila e seu uso como analgésicos"
DK0388827T3 (da) Anvendelse af 5-methyltetrahydrofolsyre, 5-formyltetrahydrofolsyre og deres farmaceutisk acceptable salte ved fremstilling af farmaceutiske præparater med kontrolleret frigivelse og aktive ved terapi af organiske mentale forstyrrelser, og de tilsvarende farmaceutiske præparater
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
Nybäck et al. Effects of piracetam on brain monoamine metabolism and serum prolactin levels in the rat
Kerwin From pharmacological profiles to clinical outcomes
DE69636934D1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
NO991292L (no) Anvendelse av benzopyranoler for Õ behandle nevrologiske forstyrrelser
BR9406034A (pt) Derivados de imidazoloquinoxalinonas como antagonistas de eaa.
WO2002030411A8 (en) Treatment of apoptotic cell death
ATE143809T1 (de) Placentaextrakt und verfahren zu seiner herstellung
OHNISHI et al. Polyneuropathy due to ethylene oxide, propylene oxide, and butylene oxide
Omotoso et al. Moringa oleifera ameliorates histomorphological changes associated with cuprizone neurotoxicity in the hippocampal cornu ammonis (CA) 3 region
WO2005009359A3 (en) Agents, compositions and methods for enhancing neurological function
Licht et al. The effect of chronic lithium treatment on the calibre of axons and nerve fibres in the rat sural nerve
Ovtscharoff Cytochemical Localization of Choline Acetyltransferase
WO2000001440A3 (en) Methods for treating neurological injuries and disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.